Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
Biogen reported revenue of $9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.2% from fiscal 2024. Net income was $1.29 billion and diluted earnings per share $8.79.
In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.80 billion, up 10.6% from a year earlier.
Figures from Biogen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 28 Oct 2026.
Against Health Care
Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.
Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Product | Revenue | Share | Change |
|---|---|---|---|
| Revenue from anti-CD20 therapeutic programs | $1.86B | 19% | +6.3% |
| SPINRAZA | $1.55B | 16% | −1.7% |
| Fumarate | $1.43B | 14% | −10.6% |
| Interferon | $945.6M | 9.6% | −2.3% |
| VUMERITY | $746.8M | 7.6% | +18.9% |
| Contract manufacturing, royalty and other revenue | $732.9M | 7.4% | +12.3% |
| Biosimilars | $729.1M | 7.4% | −8.1% |
| Other lines (3) | $1.90B | 19% | — |
Biogen beside the other S&P 500 members in Biotechnology, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| $37.52B | +1.2% | +56.9% | +2.3% | 3.4% | 108.0 | |
| $525.9B | +0.2% | +26.5% | +10.7% | 15.7% | 51.1 | |
| AmgenAMGN | $253.8B | −0.3% | +38.5% | +8.2% | 24.1% | 27.0 |
| $210.2B | +0.1% | +36.2% | +6.5% | −12.5% | — | |
| $24.67B | −0.6% | +11.7% | +24.9% | 6.7% | 61.2 | |
| — | −3.4% | +736% | — | — | — | |
| — | +0.4% | +40.2% | — | — | — |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.45B | $12.27B | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.89B |
| Revenue growth | +6.4% | +7.2% | +9.6% | +6.9% | −6.5% | −18.3% | −7.4% | −3.3% | −1.6% | +2.2% |
| Gross profit | $9.97B | $10.64B | $11.64B | $12.42B | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| Operating income | $5.15B | $5.35B | $5.89B | $7.04B | $4.55B | $2.84B | $3.84B | $1.61B | $2.25B | $1.86B |
| Net income | $3.70B | $2.54B | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Diluted EPS | $16.93 | $11.92 | $21.58 | $31.42 | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Gross margin | 87.1% | 86.7% | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% |
| Operating margin | 45.0% | 43.6% | 43.8% | 49.0% | 33.8% | 25.9% | 37.7% | 16.4% | 23.2% | 18.8% |
| Net margin | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.59B | $4.55B | $6.19B | $7.08B | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B |
| Capital expenditure | $616.1M | $867.4M | $770.6M | $514.5M | $424.8M | $258.1M | $240.3M | $277.0M | $153.7M | $153.8M |
| Free cash flow | $3.97B | $3.68B | $5.42B | $6.56B | $3.81B | $3.38B | $1.14B | $1.27B | $2.72B | $2.05B |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.33B | $1.57B | $1.22B | $2.91B | $1.33B | $2.26B | $3.42B | $1.05B | $2.38B | $3.01B |
| Total debt | $6.52B | $5.94B | $5.94B | $4.95B | $7.91B | $6.69B | $6.71B | $7.28B | $4.97B | $6.66B |
| Shareholders' equity | $12.14B | $12.61B | $13.04B | $13.34B | $10.70B | $10.90B | $13.40B | $14.80B | $16.72B | $18.26B |
| Diluted shares | 219M | 213M | 205M | 187M | 161M | 150M | 146M | 146M | 146M | 147M |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B | $2.74B | $2.80B |
| Revenue, year on year | +2.9% | +6.1% | +7.3% | +2.8% | −7.1% | +1.9% | +3.4% | +10.6% |
| Gross margin | 76.2% | 74.1% | 77.1% | 73.4% | 78.3% | 73.3% | 71.6% | 73.3% |
| Operating income | $635.1M | $311.2M | $744.0M | $557.3M | $249.6M | $377.7M | $132.4M | −$9.00M |
| Net income | $266.7M | $240.5M | $634.8M | $466.5M | −$48.90M | $319.5M | $97.50M | −$20.60M |
| Diluted EPS | $1.83 | $1.64 | $4.33 | $3.17 | −$0.33 | $2.15 | $0.66 | −$0.14 |
| Free cash flow | $721.6M | $222.2M | $134.3M | $1.23B | $468.0M | $594.3M | $408.0M | $600.4M |
The operating figures Biogen reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| Product revenue, net revenue | $2.1B | quarter to 30 Sep 2026 | up 13.1% | |
| MS Product Revenues | $919.3M | quarter to 30 Sep 2026 | down 13.4% | |
| Rare Disease Product Revenue | $676.3M | quarter to 30 Sep 2026 | up 26.8% | |
| Revenue from anti-CD20 therapeutic programs revenue | $497.3M | quarter to 30 Sep 2026 | up 0.7% | |
| SPINRAZA revenue | $460.6M | quarter to 30 Sep 2026 | up 23.2% | |
| TYSABRI revenue | $437.1M | quarter to 30 Sep 2026 | up 1.2% | |
| Royalty Attributed To OCREVUS revenue | $369.9M | quarter to 30 Sep 2026 | down 4.3% | |
| Fumarate revenue | $274.0M | quarter to 30 Sep 2026 | down 28.4% | |
| Specialized Immunology revenue | $242.8M | quarter to 30 Sep 2026 | — | |
| Interferon revenue | $208.2M | quarter to 30 Sep 2026 | down 15.7% | |
| VUMERITY revenue | $192.0M | quarter to 30 Sep 2026 | down 10.5% | |
| SYFOVRE revenue | $191.3M | quarter to 30 Sep 2026 | — | |
| SKYCLARYS revenue | $178.2M | quarter to 30 Sep 2026 | up 34.1% | |
| Biosimilars revenue | $165.9M | quarter to 30 Sep 2026 | down 15.7% | |
| AVONEX revenue | $156.6M | quarter to 30 Sep 2026 | down 16.9% | |
| Contract manufacturing, royalty and other revenue | $149.7M | quarter to 30 Sep 2026 | down 1.0% | |
| Contract manufacturing revenue | $135.9M | quarter to 30 Sep 2026 | down 4.0% | |
| BENEPALI revenue | $117.3M | quarter to 30 Sep 2026 | down 3.8% | |
| ZURZUVAE revenue | $84.4M | quarter to 30 Sep 2026 | up 52.6% | |
| TECFIDERA revenue | $82.0M | quarter to 30 Sep 2026 | down 51.2% | |
| Alzheimer's Collaboration revenue | $68.4M | quarter to 30 Sep 2026 | up 60.2% | |
| PLEGRIDY revenue | $51.6M | quarter to 30 Sep 2026 | down 11.6% | |
| EMPAVELI revenue | $51.5M | quarter to 30 Sep 2026 | — | |
| IMRALDI revenue | $42.0M | quarter to 30 Sep 2026 | down 20.2% | |
| QALSODY revenue | $37.5M | quarter to 30 Sep 2026 | up 42.0% | |
| Royalty and other revenue | $13.8M | quarter to 30 Sep 2026 | up 42.3% | |
| FLIXABI revenue | $6.4M | quarter to 30 Sep 2026 | down 58.2% | |
| BYOOVIZ revenue | $200,000 | quarter to 30 Sep 2026 | down 97.1% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.
$1.29 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).
$8.79 for fiscal year 2025 (the twelve months to 31 Dec 2025).
75.7% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.
18.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.
$2.05 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.
In fiscal 2025, by product: Revenue from anti-CD20 therapeutic programs $1.86B (19%), SPINRAZA $1.55B (16%), Fumarate $1.43B (14%), Interferon $945.6M (9.6%), out of $9.89B in all, as stated in its annual report.
In the terminal